Tactile Systems (TCMD) Q2 Revenue Up 8%

Tactile Systems Technology (NASDAQ:TCMD), a medical technology company focused on chronic disease therapy devices, posted its financial results for the second quarter of fiscal 2025 on August 4, 2025. The standout result from the release was stronger-than-expected revenue, which exceeded analyst estimates for Q2 2025 (GAAP), led by impressive gains in the airway clearance business. GAAP revenue was $78.9 million in Q2 2025, ahead of the $73.9 million GAAP consensus estimate, and diluted earnings per share (GAAP) reached $0.14 in Q2 2025, beating the $0.1075 GAAP expectation. However, GAAP net income and Adjusted EBITDA both declined year over year, reflecting increased operating expenses tied to strategic investments in sales and technology. The quarter marked positive momentum, as total revenue increased 7.8% year-over-year to $78.9 million and product adoption but underscored continued challenges in profitability as the business invests for future growth. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Tactile Systems Technology develops and sells medical devices for patients with lymphedema, a condition causing swelling due to lymphatic system issues, and for those needing help with airway clearance. Its main products include Flexitouch and Entre Plus pneumatic compression systems for lymphedema, and the wearable AffloVest for airway clearance. The company’s mission centers around providing devices that improve daily living and clinical outcomes for people with chronic conditions.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool